ARO-C3
RNA / oligonucleotide
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05083364 NCT05083364 · Complement-Mediated Renal Disease Registry: NCT05083364 | 1/2 | Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs) at Day 169 (up to day 169 (End of Study [EOS])) 2025-09-10 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
Other Complement C3 drugs
Pegcetacoplan, Pegcetacoplan ophthalmic, Cevolisiran. Compare all 4 Complement C3 drugs
3 other tracked programmes target this mechanism, 3 of them ahead of this one.
This drug's own stage for Complement-Mediated Renal Disease: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| ARO-C3: this drug | Phase 1/2 | RNA / oligonucleotide | Complement C3 | not yet graded | No reviewed efficacy summary in this indication | |
| Iptacopan (Fabhalta) | Approved | Small molecule | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication | |
| Pegcetacoplan (Empaveli) | Approved | Peptide | Complement C3 | not yet graded | No reviewed efficacy summary in this indication | |
| Pegcetacoplan Ophthalmic (Syfovre) | Approved(overall) | Peptide | Complement C3, Complement C3 / C3b | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Cevolisiran | Phase 2(overall) | RNA / oligonucleotide | Complement C3 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent